Deudomperidone - CinRx Pharma
Alternative Names: CIN-102; Deuterated domperidone; Domperidone deuterated - CinRx PharmaLatest Information Update: 08 Sep 2025
At a glance
- Originator CinRx Pharma
- Developer CinDome Pharma
- Class Antiemetics; Benzimidazoles; Chlorinated hydrocarbons; Gastrokinetics; Organic deuterium compounds; Piperidines; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Gastroparesis
Most Recent Events
- 04 Sep 2025 CinDome announces intention to engage with the US FDA to evaluate the registrational path forward for deudomperidone
- 04 Sep 2025 CinDome Pharma completes enrolment phase II envision3D trial for Diabetic gastroparesis in the USA (NCT05832151)
- 04 Jun 2025 Phase-II clinical trials in Gastroparesis in USA (PO) (NCT06899217)